Prior morphine exposure enhances ibogaine antagonism of morphine-induced locomotor stimulation.
S M Pearl, D W Johnson, Stanley D Glick
Psychopharmacology October 1, 1995 DOI: 10.1007/bf02246495 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental study Peer reviewed |
|---|---|
| Population | Female Sprague-Dawley rats |
| Interventions | Morphine Ibogaine |
| Dose | morphine: 5, 10, 20 or 30 mg/kg, i.p.; ibogaine: 40 mg/kg, i.p. (also tested 5-60 mg/kg, i.p.) |
| Duration | 1-4 days of morphine pretreatment, ibogaine administered 5 h after last morphine dose, testing 29 h after ibogaine |
| Topics | Ibogaine |
| Citations | 31 |
| Key findings | Prior morphine exposure enhances ibogaine's ability to reduce morphine-induced locomotor stimulation in rats, suggesting that individual histories of opioid exposure may affect ibogaine's efficacy against opioid addiction. |
Abstract
Ibogaine is currently being investigated for its potential use as an anti-addictive agent. In the present study we sought to determine whether prior morphine exposure influences the ability of ibogaine to inhibit morphine-induced locomotor stimulation. Female Sprague-Dawley rats were pretreated once a day for 1-4 days with morphine (5, 10, 20 or 30 mg/kg, i.p.) or saline and then received ibogaine (40 mg/kg, i.p.) 5 h after the last morphine pretreatment dose. Compared to rats pretreated with saline, rats pretreated with morphine (10, 20 or 30 mg/kg, i.p.) before ibogaine (40 mg/kg, i.p.) showed a significant reduction in morphine-induced (5 mg/kg, i.p.) locomotor stimulation when tested 29 h after ibogaine administration. Furthermore, this effect was apparent over a range of ibogaine (5-60 mg/kg, i.p.) and morphine test (2.5-5 mg/kg, i.p.) dosages. Doses of ibogaine (5 and 10 mg/kg, i.p.) which alone were inactive inhibited morphine-induced locomotor activity when rats had been pretreated with morphine. These results, showing that morphine pre-exposure affects ibogaine activity, suggest that variable histories of opioid exposure might account for individual differences in the efficacy of ibogaine to inhibit opioid addiction.